# Versant Venture Management, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1560009. Source: https://holderbook.com/funds/1560009-versant-venture-management-llc/

- Reported value: $162.6M
- Positions: 8
- Weight of the ten largest: 100.0%
- Filed: 2026-08-12

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $77.0M | 3,180,780 | 47.3% | 7 |
| CENTURY THERAPEUTICS INC | [IPSC](https://holderbook.com/stocks/IPSC/) | $29.8M | 12,166,109 | 18.3% | 2 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $22.0M | 991,783 | 13.6% | 5 |
| LENZ THERAPEUTICS INC | [LENZ](https://holderbook.com/stocks/LENZ/) | $15.1M | 2,656,888 | 9.3% | 4 |
| CONTINEUM THERAPEUTICS INC | [CTNM](https://holderbook.com/stocks/CTNM/) | $8.9M | 542,628 | 5.5% | 9 |
| CRISPR THERAPEUTICS AG | [CRSP](https://holderbook.com/stocks/CRSP/) | $8.1M | 148,831 | 5.0% | 31 |
| SKYE BIOSCIENCE INC | [SKYE](https://holderbook.com/stocks/SKYE/) | $1.4M | 2,007,704 | 0.9% | 10 |
| TEMPEST THERAPEUTICS INC | [TPST](https://holderbook.com/stocks/TPST/) | $299.4K | 269,772 | 0.2% | 5 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +23.6% | +14.8% | +8.7% | 100% |
| Q1 2026 | -11.3% | -4.6% | -6.7% | 99% |
| Q4 2025 | -14.6% | +2.4% | -17.0% | 98% |
| Q3 2025 | +34.2% | +7.8% | +26.4% | 96% |
| Q2 2025 | +18.1% | +10.5% | +7.7% | 92% |
| Q1 2025 | -31.3% | -4.6% | -26.7% | 97% |
| Q3 2024 | -14.3% | +5.4% | -19.7% | 95% |
| Q2 2024 | -34.0% | +4.0% | -38.0% | 63% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $162.6M | 8 |
| Q1 2026 | $141.4M | 8 |
| Q4 2025 | $151.1M | 7 |
| Q3 2025 | $212.5M | 9 |
| Q2 2025 | $82.1M | 8 |
| Q1 2025 | $60.2M | 7 |
| Q4 2024 | $86.7M | 7 |
| Q3 2024 | $63.6M | 6 |
| Q2 2024 | $77.3M | 8 |
| Q1 2024 | $103.1M | 7 |
| Q4 2023 | $388.8M | 7 |
| Q3 2023 | $188.1M | 8 |